Megan has actively engaged with Pfizer’s US Policy & Government Relations colleagues to help educate congressional staffers on Pfizer’s oncology vision and strategy. Additionally, she serves as a member of Pfizer’s Political Contributions Policy Committee.
Jeff is a leader in the rheumatology community. He is also a fierce advocate for patient awareness and rights. He was instrumental in creating the HS Coalition, which helps enhance awareness and diagnosis of this chronic inflammatory skin condition.
Victoria leads a dedicated team, motivating them to prioritize patients and community needs in their everyday decisions. A paramount focus of her efforts has been to enhance access to prostate cancer education and screening for African American and Hispanic communities in St. Louis and Nashville.
Savine has spearheaded impactful engagement programs with trusted partners like the National Minority Quality Forum, the HEAL Collaborative, and others to raise awareness around Alzheimer’s disease, lupus, and the importance of clinical trials for underrepresented groups. Additionally, Savine consistently advances Biogen’s clinical trial policy work by engaging with key stakeholders in Washington, DC.
Phung has been a leading voice in expanding patient access to transformative CAR-T therapies. She has worked closely with treatment centers, payers, and patient organizations to improve understanding of cell therapy access barriers and to develop solutions that ensure patients can receive timely, equitable care.
Colleen has effectively amplified the patient voice through legislative advocacy, community outreach, and educational programs. She has created a successful model for community engagement during key congresses, bringing together healthcare providers, patient advocacy organizations, and community health workers to address health disparity gaps. She actively raises awareness in underserved communities, engages stakeholders in meaningful dialogue
Oscar has a proven track record of working tirelessly to bridge the gaps between patients and innovative medicines. He participates in state capitol meetings and uses his expertise to educate lawmakers and push for change to address broader access issues, drive representation in clinical trials, and build understanding around the need for new innovations.
Woodie is a partner to Gilead’s Government Affairs team who knows how to think about issues from a policy and economic lens – and in doing so, has helped create research that often supports our policy objectives. He has helped prepare Gilead’s responses to PDABs on HIV and is the co-lead on the evidence generation
In addition to leading one of the U.S. sales teams for GSK’s Respiratory business, Anton also serves as the Vice Chair of the GSK PAC Board of Directors. His leadership has driven higher employee participation in the GSK PAC Ambassador program and encouraged employees to pursue future opportunities for the PAC.
Outside of helping change the treatment landscape for people with bladder cancer, Dr. Cutie is also engaged in the legislative world. In June 2025, he participated in the PhRMA Researcher Fly-In. He spoke to policymakers about the physical and mental health challenges of patients facing a bladder cancer diagnosis and his work in building toward